Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial.

Autor: Ramaswamy A; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Bhargava P; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Srinivas S; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Kapoor A; Department of Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi, India., Mishra BK; Department of Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi, India., Gupta A; Department of Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi, India., Mandavkar S; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Kannan S; Department of Statistics, Advanced Centre for Treatment, Research and Education in Cancer, Homi Bhabha National Institute (HBNI), Mumbai, India., Chaugule D; CRC, Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Patil R; CRC, Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Parulekar M; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Nashikkar C; Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Ankathi SK; Department of Radiology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Kaushal RK; Department of Pathology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Naughane D; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Daddi A; Department of Medicine, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Mer N; CRC, Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Shetty N; Department of Radiology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Ostwal V; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Sep 20; Vol. 42 (27), pp. 3218-3227. Date of Electronic Publication: 2024 Aug 05.

Adjuvant Gemcitabine Plus Cisplatin and Chemoradiation in Patients With Gallbladder Cancer: A Randomized Clinical Trial.

Autor: Ostwal V; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India., Patkar S; Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India., Engineer R; Department of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India., Parulekar M; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India., Mandavkar S; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India., Bhargava P; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India., Srinivas S; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India., Krishnatry R; Department of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India., Gudi S; Department of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India., Kapoor A; Department of Medical Oncology, Mahanama Pandit Madan Mohan Malviya Cancer Centre and Homi Bhabha Cancer hospital, Tata Memorial Centre, Varanasi, India., Pandey D; Department of Surgical Oncology, Mahanama Pandit Madan Mohan Malviya Cancer Centre and Homi Bhabha Cancer hospital, Tata Memorial Centre, Varanasi, India., Patel S; Department of Surgical Oncology, Mahanama Pandit Madan Mohan Malviya Cancer Centre and Homi Bhabha Cancer hospital, Tata Memorial Centre, Varanasi, India., Singhal A; Department of Radiation Oncology, Mahanama Pandit Madan Mohan Malviya Cancer Centre and Homi Bhabha Cancer hospital, Tata Memorial Centre, Varanasi, India., Goel A; Department of Medical Oncology, Homi Bhabha Cancer Hospital (HBCH), Civil Hospital Campus, Sangrur, India., Dora TK; Department of Medical Oncology, Homi Bhabha Cancer Hospital (HBCH), Civil Hospital Campus, Sangrur, India., Chaudhary D; Department of Surgical Oncology, Homi Bhabha Cancer Hospital (HBCH), Civil Hospital Campus, Sangrur, India., Chaugule D; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Naughane D; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Daddi A; Department of Medicine, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Patil R; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Ankathi SK; Department of Radiodiagnosis, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India., Ramaswamy A; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Goel M; Department of Surgical Oncology, TMH, Mumbai, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.

Publikováno v: JAMA oncology [JAMA Oncol] 2024 Aug 01; Vol. 10 (8), pp. 1116-1120.

Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers.

Autor: Ramaswamy A; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Bhargava P; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Dubashi B; Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India., Gupta A; Department of Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi, India., Kapoor A; Department of Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi, India., Srinivas S; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Shetty O; Department of Molecular Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Jadhav P; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Desai V; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Noronha V; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Joshi A; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Menon N; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Patil VM; Consultant Medical Oncologist, P.D. Hinduja Hospital & Medical Research Centre, Mumbai, India., Mishra BK; Department of Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi, India., Sansar B; Department of Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi, India., Singh A; Department of Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi, India., Patel S; Department of Surgical Oncology, Homi Bhabha Cancer Hospital, Varanasi, India., Singh SN; Department of Radiology, Homi Bhabha Cancer Hospital, Varanasi, India., Dhal I; Department of Pathology, Homi Bhabha Cancer Hospital, Varanasi, India., Vinayak KR; Department of Palliative Medicine, Homi Bhabha Cancer Hospital, Varanasi, India., Pal V; Department of Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi, India., Mandavkar S; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Kannan S; Department of Statistics, Advanced Centre for Treatment, Research and Education in Cancer, Homi Bhabha National Institute (HBNI), Mumbai, India., Chaugule D; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Patil R; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Parulekar M; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Nashikkar C; Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Ankathi SK; Department of Radiodiagnosis, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Kaushal RK; Department of Pathology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Shah A; Department of Pathology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Ganesan P; Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India., Kayal S; Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India., Ananthakrishnan R; Department of Radiodiagnosis, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India., Syed N; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Samaddar D; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Kapu V; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Shah A; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Kaaviya D; Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India., Suganiya R; Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India., Srinivasan ND; Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India., Prabhash K; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Ostwal V; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.

Publikováno v: JNCI cancer spectrum [JNCI Cancer Spectr] 2024 Jul 01; Vol. 8 (4).

Gemcitabine, Cisplatin, and Nab-Paclitaxel as a First-Line Therapy for Advanced Biliary Tract Cancers.

Autor: Gedela S; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Dr. E Borges Road, Parel, Mumbai, 400 012, India., Munot P; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Dr. E Borges Road, Parel, Mumbai, 400 012, India., Vaidyanathan A; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Dr. E Borges Road, Parel, Mumbai, 400 012, India., Joarder R; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Dr. E Borges Road, Parel, Mumbai, 400 012, India., Chaugule D; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Dr. E Borges Road, Parel, Mumbai, 400 012, India., Parulekar M; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Dr. E Borges Road, Parel, Mumbai, 400 012, India., Nashikkar C; Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Dr. E Borges Road, Parel, Mumbai, 400 012, India., Ghadi A; Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Dr. E Borges Road, Parel, Mumbai, 400 012, India., Vadodaria D; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Dr. E Borges Road, Parel, Mumbai, 400 012, India., Goel M; Gastrointestinal & HPB Surgery, Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Dr. E Borges Road, Parel, Mumbai, 400 012, India., Patkar S; Department of Surgical Oncology, GI & HPB Services, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Dr. E Borges Road, Parel, Mumbai, 400 012, India., Mandavkar S; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Dr. E Borges Road, Parel, Mumbai, 400 012, India., Ramaswamy A; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Dr. E Borges Road, Parel, Mumbai, 400 012, India., Bhargava P; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Dr. E Borges Road, Parel, Mumbai, 400 012, India., Srinivas S; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Dr. E Borges Road, Parel, Mumbai, 400 012, India., Ostwal V; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Dr. E Borges Road, Parel, Mumbai, 400 012, India. dr.vikas.ostwal@gmail.com.

Publikováno v: Journal of gastrointestinal cancer [J Gastrointest Cancer] 2024 Mar; Vol. 55 (1), pp. 263-269. Date of Electronic Publication: 2023 Jun 27.

SIOG2023-1-OA-101 - Randomized phase III clinical trial:Non-inferiority of reduced dose chemotherapy based on CARG

Autor: Kumar, A., Ostwal, V., Bhargava, P., Srinivas, S., Rao, A., Pillai, A., Mahajan, S., Dhekle, R., Sonkusare, L., Mahajan, P., Mandavkar, S., Parulkar, M., Prabhash, K., Noronha, V., Ramaswamy, A.

Publikováno v: In Journal of Geriatric Oncology November 2023 14(8) Supplement 1:S1-S2